drugset / Trial / NCT06614608

The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

NCT06614608

Phase 1 Not yet recruiting 24 enrolled Jiangsu Aosaikang Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, randomized, double-blind clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKC200 in subjects with OA of the knees and determine the phase II recommended dose. Assigned doses will be applied for 60 minutes on each of four consecutive days.

Timeline

Start
2024-10
Primary completion
2025-04
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 1 % Topical
Subject Capsaicin Small molecule 5 % Topical

Indications